Investor Presentaiton
Prescriptions (TRX, 000s)
Lilly
Robust U.S. uptake bolstered by strong
efficacy and a positive customer experience
MOUNJARO U.S. LAUNCH PROGRESS
250
200
150
once weekly
▲ mounjaro
(tirzepatide) injection
тит
100
50
50
Mounjaro TRX
Mounjaro Paid TRX*
Trulicity TRX
Semaglutide TRX
L+1
L+4
L+7
L+10
L+13
L+16
L+19
L+22
L+25
L+28
L+31
L+34
L+37
L+40
L+43
L+46
L+49
L+52
L+55
Weeks Post Launch
Mounjaro volume has significantly outpaced prior launches in the
type 2 diabetes injectable incretin class
*Internal estimate of weekly paid TRX
IQVIA weekly data for week ending June 30, 2023 (type 2 diabetes injectable incretin class)
Not for promotional use
Access as of July 1st at 73% for patients with
type 2 diabetes across total commercial and
Part D lives
Percentage of paid prescriptions rose to 67%
in Q2 due to copay program dynamics and
improved access
Original non-covered $25 copay card ended
June 30
Focus on driving new-to-brand growth while.
continuing access expansion
2023 Q2 EARNINGS
11View entire presentation